Illumina files sweeping appeal of EU Commission's Grail merger prohibition
By Natalie McNelis ( November 18, 2022, 08:39 GMT | Insight) -- Illumina last night filed a sweeping appeal of the European Commission’s veto of its bid to take over cancer-testing specialist Grail, MLex has learned. The US life sciences company’s appeal attacks the prohibition decision in all its aspects, both procedurally and substantively, and relies throughout on the alleged weakness of the regulator’s use of the innovation theory of harm.Illumina last night filed a sweeping appeal of the European Commission’s veto of its bid to take over cancer-testing specialist Grail, MLex has learned....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.